Allogene Therapeutics unveils strategy to overcome autologous CAR T cell therapy limitations

Allogene Therapeutics unveils strategy to overcome autologous CAR T cell therapy limitations
Allogene Therapeutics pushes CAR T

Allogene Therapeutics is advancing its investigational AlloCAR T products as it seeks to redefine the CAR T cell therapy landscape.

The company highlights the potential of allogeneic, or off-the-shelf, cell therapies to enable greater speed, scalability, and patient access compared to autologous treatments. This next-generation approach aims to address key bottlenecks that have limited broader use of CAR T cell therapy for patients in need.

Allogene has previously addressed early ALPHA3 safety data and reviewed the use of investigational cema-cel for MRD-positive LBCL outpatients in a recent update (article). The company also launched the ALPHA3 trial using MRD testing to target relapse in LBCL patients (article). These efforts highlight its ongoing development of allogeneic CAR T treatments.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.